Novartis inks $1B-plus biobucks deal with Flagship’s Generate (September 24, 2024) | By Gabrielle Masson. Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop protein therapeutics across multiple indications. The companies did not disclose specifics about potential disease areas, referring only to the pact as a “multi-target collaboration”
Summary – Explore groundbreaking biotechnology advancements with Ross, an inventor with 75 patents. Discover how his work is unlocking nature’s hidden molecules and revolutionizing the health and technology sectors.
Scilex’s Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect (September 3, 2024) | By Zoey Becker. Semnur Pharmaceuticals, which is working on a non-opioid prospect for sciatica, has agreed to merge with special purpose acquisition company Denali Capital Acquisition Corp. in a deal worth $2.5 billion. Upon closure of
